PE20241349A1 - Anticuerpos de union a cd3 - Google Patents

Anticuerpos de union a cd3

Info

Publication number
PE20241349A1
PE20241349A1 PE2024000894A PE2024000894A PE20241349A1 PE 20241349 A1 PE20241349 A1 PE 20241349A1 PE 2024000894 A PE2024000894 A PE 2024000894A PE 2024000894 A PE2024000894 A PE 2024000894A PE 20241349 A1 PE20241349 A1 PE 20241349A1
Authority
PE
Peru
Prior art keywords
seq
cdr2
cdr3
antigen
chain variable
Prior art date
Application number
PE2024000894A
Other languages
English (en)
Inventor
Nathan Trinklein
Schooten Wim Van
Shelley Force Aldred
Katherine Harris
Duy Pham
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of PE20241349A1 publication Critical patent/PE20241349A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a un anticuerpo multiespecifico caracterizado porque comprende: (i) un primer resto de union que tiene especificidad de union a CD3[deltaepsilon], que comprende: un dominio variable de cadena pesada que comprende: (A) una secuencia de CDR1 de SEQ ID NO: 29, una CDR2 de SEQ ID NO: 24, y una CDR3 de SEQ ID NO: 41; o (B) una CDR1 de SEQ ID NO: 34, una CDR2 de SEQ ID NO: 24 y una CDR3 de SEQ ID NO: 43; y un dominio variable de cadena liviana que comprende una secuencia de CDR1 de SEQ ID NO: 35, una CDR2 de SEQ ID NO: 38 y una CDR3 de SEQ ID NO: 45; y (ii) un segundo resto de union que tiene especificidad de union para un antigeno de diferenciacion hematopoyetica, un antigeno de diferenciacion de la superficie celular, un antigeno de senalizacion del factor de crecimiento, o un antigeno de matriz extracelular. Tambien se refiere a la produccion de dichos anticuerpos multiespecificos, una composicion farmaceutica que los comprende y su uso en el tratamiento del cancer.
PE2024000894A 2016-09-14 2017-06-20 Anticuerpos de union a cd3 PE20241349A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394360P 2016-09-14 2016-09-14
US201762491908P 2017-04-28 2017-04-28
PCT/US2017/038377 WO2018052503A1 (en) 2016-09-14 2017-06-20 Cd3 binding antibodies

Publications (1)

Publication Number Publication Date
PE20241349A1 true PE20241349A1 (es) 2024-07-03

Family

ID=61619675

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019000520A PE20190976A1 (es) 2016-09-14 2017-06-20 Anticuerpos de union a cd3
PE2024000894A PE20241349A1 (es) 2016-09-14 2017-06-20 Anticuerpos de union a cd3

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2019000520A PE20190976A1 (es) 2016-09-14 2017-06-20 Anticuerpos de union a cd3

Country Status (31)

Country Link
US (4) US11505606B2 (es)
EP (3) EP3512549A4 (es)
JP (6) JP7030109B2 (es)
KR (4) KR20240044520A (es)
CN (3) CN117603353A (es)
AU (2) AU2017327723B2 (es)
BR (2) BR112019004873A2 (es)
CA (1) CA3036550A1 (es)
CL (4) CL2019000643A1 (es)
CO (1) CO2019003706A2 (es)
CR (3) CR20220578A (es)
DK (1) DK4050034T3 (es)
DO (3) DOP2019000059A (es)
EC (1) ECSP19026304A (es)
ES (1) ES2980623T3 (es)
FI (1) FI4050034T3 (es)
HR (1) HRP20240767T1 (es)
HU (1) HUE066651T2 (es)
IL (3) IL290517B1 (es)
LT (1) LT4050034T (es)
MX (2) MX2019002967A (es)
PE (2) PE20190976A1 (es)
PH (1) PH12019500545A1 (es)
PL (1) PL4050034T3 (es)
PT (1) PT4050034T (es)
RS (1) RS65595B1 (es)
SA (2) SA522431672B1 (es)
SI (1) SI4050034T1 (es)
UA (1) UA126384C2 (es)
WO (1) WO2018052503A1 (es)
ZA (1) ZA202203250B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471773A4 (en) * 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
PT4050034T (pt) * 2016-09-14 2024-05-27 Teneoone Inc Anticorpos de ligação a cd3
IL300729A (en) 2016-12-21 2023-04-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. ANTIBODIES ONLY TO HEAVY ANTI-BCMA CHAINS
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
SG11202006042SA (en) * 2017-12-27 2020-07-29 Teneobio Inc Cd3-delta/epsilon heterodimer specific antibodies
PE20210132A1 (es) 2018-05-24 2021-01-19 Janssen Biotech Inc Anticuerpos anti-cd3 y usos de estos
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
SG11202011597RA (en) 2018-07-20 2020-12-30 Teneobio Inc Heavy chain antibodies binding to cd19
US10867104B2 (en) * 2018-08-31 2020-12-15 Taiwan Semiconductor Manufacturing Company Ltd. Isolation circuit between power domains
JP2022505445A (ja) 2018-10-26 2022-01-14 テネオバイオ， インコーポレイテッド Ｃｄ３８に結合する重鎖抗体
CN113710707B (zh) 2019-04-05 2024-05-31 特尼奥生物股份有限公司 结合于psma的重链抗体
MX2021015337A (es) 2019-06-14 2022-01-18 Teneobio Inc Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
WO2021022304A2 (en) * 2019-07-30 2021-02-04 Qlsf Biotherapeutics, Inc. MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε
CN112574308A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
MX2022007613A (es) 2019-12-18 2022-07-19 Teneofour Inc Union de anticuerpos de cadena pesada a cd38.
PE20230431A1 (es) 2020-04-29 2023-03-08 Teneobio Inc Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas
WO2021222578A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
EP4142791A1 (en) 2020-04-29 2023-03-08 TeneoOne, Inc. Methods of treating multiple myeloma
MX2022016342A (es) 2020-06-30 2023-01-24 Teneobio Inc Union de anticuerpos multiespecificos a bcma.
JP2023542257A (ja) 2020-09-16 2023-10-05 アムジェン インコーポレイテッド 癌の治療のために二重特異性ｔ細胞誘導分子の治療用量を投与する方法
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
CN117500835A (zh) 2021-02-25 2024-02-02 特尼奥生物股份有限公司 抗psma抗体及car-t结构
JP2024508808A (ja) 2021-02-26 2024-02-28 テネオバイオ， インコーポレイテッド 抗ｍｕｃ１－ｃ抗体及びｃａｒ－ｔ構造
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
AU2022255709A1 (en) 2021-04-06 2023-09-28 Teneobio, Inc. Anti-cd19 antibodies and car-t structures
PE20240656A1 (es) 2021-04-16 2024-04-04 Teneobio Inc Anticuerpos anti-cd20 y estructuras car-t
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
KR20240021289A (ko) * 2021-06-24 2024-02-16 엑사이트 바이오파마 리미티드 Bcma 및 cd3에 결합하는 이중특이성 항체 및 그 제조 방법과 응용
WO2023288191A1 (en) * 2021-07-13 2023-01-19 University Of Washington Multiple de novo designed protein binding proteins
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen
JP2024531944A (ja) 2021-08-09 2024-09-03 ハーバー バイオメッド（シャンハイ）カンパニー リミテッド Ｃｌｄｎ１８．２標的化抗体、二重特異性抗体、及びそれらの使用
WO2023064876A1 (en) 2021-10-14 2023-04-20 Teneobio, Inc. Mesothelin binding proteins and uses thereof
WO2024026358A1 (en) 2022-07-27 2024-02-01 Teneobio, Inc. Mesothelin binding proteins and uses thereof
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024178056A1 (en) 2023-02-21 2024-08-29 Teneobio, Inc. C-kit binding proteins, chimeric antigen receptors, and uses thereof
KR20240139569A (ko) * 2023-03-13 2024-09-23 머스트바이오 주식회사 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
PT1642972E (pt) 1999-01-07 2010-04-07 Zymogenetics Inc Utilizações terapêuticas de receptores solúveis br43x2
IL148089A0 (en) 1999-08-17 2002-09-12 Biogen Inc Baff receptor (bcma), an immunorgulatory agent
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
AU2001261557B2 (en) 2000-05-12 2005-06-30 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
WO2002059264A2 (en) * 2000-12-29 2002-08-01 Bio-Technology General Corp. Specific human antibodies for selective cancer therapy
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7919089B2 (en) 2003-05-31 2011-04-05 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for EpCAM
AU2004283850C1 (en) 2003-10-16 2011-11-03 Amgen Research (Munich) Gmbh Multispecific deimmunized CD3-binders
EP2865687A1 (en) * 2003-12-10 2015-04-29 E. R. Squibb & Sons, L.L.C. IP-10 antibodies and their uses
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
BRPI0607203A2 (pt) 2005-02-18 2009-08-25 Medarex Inc anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009507838A (ja) 2005-09-12 2009-02-26 ノビミューン エスアー 抗ｃｄ３抗体製剤
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
WO2007042289A2 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
WO2007055916A2 (en) 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
CN101426815A (zh) 2005-12-06 2009-05-06 杜门蒂斯有限公司 具有表皮生长因子受体和/或血管内皮生长因子结合特异性的配体及其使用方法
EP3456351A1 (en) 2006-04-05 2019-03-20 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
US7862813B2 (en) 2006-07-29 2011-01-04 Bjork Jr Robert Lamar Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
EA200970250A1 (ru) * 2006-09-05 2010-02-26 Медарекс, Инк. Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
KR101589759B1 (ko) 2007-04-03 2016-01-29 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 ｃｄ３―입실론 결합 도메인
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
AU2008259939B2 (en) 2007-06-01 2014-03-13 Open Monoclonal Technology, Inc. Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
JP5739326B2 (ja) 2008-04-25 2015-06-24 ザイモジェネティクス， インコーポレイテッド Ｂ細胞上でのｂｃｍａタンパク発現レベル及び診断法における使用
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
EP2370467B1 (en) 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
PT2352763E (pt) 2008-10-01 2016-06-02 Amgen Res (Munich) Gmbh Anticorpos biespecíficos de cadeia única com especificidade para antigénios-alvo com elevado peso molecular
PT2356153T (pt) 2008-10-01 2016-07-15 Amgen Res (Munich) Gmbh Anticorpo biespecífico, de cadeia única, amepxcd3, específico interespécies
US10981998B2 (en) 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
PL2406284T3 (pl) 2009-03-10 2017-09-29 Biogen Ma Inc. Przeciwciała anty-bcma
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
RS55315B2 (sr) * 2010-02-08 2020-08-31 Regeneron Pharma Miš sa zajedničkim lakim lancem
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
EP2640750A1 (en) 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents and methods for treating diseases that correlate with bcma expression
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ， インク． 二重特異性三鎖抗体様分子
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
PT3415531T (pt) 2011-05-27 2023-09-12 Glaxo Group Ltd Proteínas de ligação a bcma (cd269/tnfrsf17
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
SG11201406346SA (en) 2012-04-20 2014-11-27 Emergent Product Dev Seattle Cd3 binding polypeptides
BR112014032916A2 (pt) * 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US10002206B2 (en) 2012-10-26 2018-06-19 Saturn Licensing Llc Information processing device and information processing method
AU2013340799B2 (en) 2012-11-01 2018-08-09 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) An antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
WO2014093908A2 (en) 2012-12-14 2014-06-19 Omt, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
EP2762496A1 (en) * 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
JP2016507523A (ja) 2013-02-05 2016-03-10 エンクマフ アーゲー ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
EP3063173B1 (en) 2013-10-31 2020-07-29 Sanofi Specific anti-cd38 antibodies for treating human cancers
AU2014343636A1 (en) 2013-11-04 2016-06-02 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
US10106623B2 (en) 2014-02-12 2018-10-23 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
TWI754319B (zh) * 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
MX2017001011A (es) * 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
AU2014409276A1 (en) 2014-10-22 2017-04-06 Crescendo Biologics Limited Transgenic mice
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
SI3221357T1 (sl) * 2014-11-20 2020-09-30 F. Hoffmann-La Roche Ag Pogoste lahke verige in načini uporabe
DK3628687T3 (da) 2014-12-12 2021-10-18 2Seventy Bio Inc Kimære bcma-antigenreceptorer
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
GB201500461D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
EP3056512A1 (en) * 2015-02-10 2016-08-17 Medizinische Universität Wien Antibody construct
CN106211261B (zh) 2015-04-10 2020-10-16 中兴通讯股份有限公司 信息处理方法及通信节点
EP4219561A3 (en) 2015-05-20 2023-11-08 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN108350076B (zh) 2015-08-17 2022-06-07 詹森药业有限公司 抗-bcma抗体，结合bcma和cd3的双特异性抗原结合分子及其用途
JP2019503167A (ja) 2015-11-10 2019-02-07 ユニバーシティ・メディカル・センター・ハンブルク−エッペンドルフＵｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Ｈａｍｂｕｒｇ − Ｅｐｐｅｎｄｏｒｆ Ｃｄ３８に対する抗原結合性ポリペプチド
EP3471773A4 (en) 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
US20190225671A1 (en) 2016-08-24 2019-07-25 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
PT4050034T (pt) * 2016-09-14 2024-05-27 Teneoone Inc Anticorpos de ligação a cd3
IL300729A (en) 2016-12-21 2023-04-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. ANTIBODIES ONLY TO HEAVY ANTI-BCMA CHAINS
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
ES2928296T3 (es) 2017-06-30 2022-11-16 Us Health Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
SG11202006042SA (en) * 2017-12-27 2020-07-29 Teneobio Inc Cd3-delta/epsilon heterodimer specific antibodies
EP3801551A4 (en) * 2018-05-24 2022-04-06 Ayala Pharmaceuticals Inc. COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USE THEREOF
SG11202011597RA (en) 2018-07-20 2020-12-30 Teneobio Inc Heavy chain antibodies binding to cd19
US20210355215A1 (en) 2018-09-21 2021-11-18 Teneobio, Inc. Methods for purifying heterodimeric, multispecific antibodies
JP2022505445A (ja) 2018-10-26 2022-01-14 テネオバイオ， インコーポレイテッド Ｃｄ３８に結合する重鎖抗体
CN113710707B (zh) 2019-04-05 2024-05-31 特尼奥生物股份有限公司 结合于psma的重链抗体
MX2021015337A (es) * 2019-06-14 2022-01-18 Teneobio Inc Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
WO2021222578A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
PE20230431A1 (es) 2020-04-29 2023-03-08 Teneobio Inc Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas
EP4142791A1 (en) 2020-04-29 2023-03-08 TeneoOne, Inc. Methods of treating multiple myeloma
US20220235380A1 (en) * 2021-01-26 2022-07-28 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
WO2023064876A1 (en) * 2021-10-14 2023-04-20 Teneobio, Inc. Mesothelin binding proteins and uses thereof

Also Published As

Publication number Publication date
CO2019003706A2 (es) 2019-06-28
RU2019111037A3 (es) 2020-11-26
EP4050034A1 (en) 2022-08-31
JP7521729B2 (ja) 2024-07-24
CR20190198A (es) 2019-10-11
JP7521728B2 (ja) 2024-07-24
KR20240044520A (ko) 2024-04-04
AU2017327723B2 (en) 2022-11-17
PT4050034T (pt) 2024-05-27
AU2022201278B2 (en) 2022-04-21
JP7321303B2 (ja) 2023-08-04
IL265321B2 (en) 2024-01-01
ZA202203250B (en) 2022-05-25
SI4050034T1 (sl) 2024-07-31
KR20220032640A (ko) 2022-03-15
DOP2019000059A (es) 2019-06-16
DOP2022000233A (es) 2022-11-30
CN109843325B (zh) 2023-10-03
JP2024023252A (ja) 2024-02-21
JP2023156342A (ja) 2023-10-24
CL2019000643A1 (es) 2019-08-09
DK4050034T3 (da) 2024-06-03
EP3512549A4 (en) 2020-06-17
AU2022201278A1 (en) 2022-03-17
KR20230035706A (ko) 2023-03-14
CR20220408A (es) 2022-10-20
JP7431868B2 (ja) 2024-02-15
EP4050034B1 (en) 2024-05-08
JP2022061992A (ja) 2022-04-19
SA522431672B1 (ar) 2023-11-12
PH12019500545A1 (en) 2019-07-29
CA3036550A1 (en) 2018-03-22
UA126384C2 (uk) 2022-09-28
BR122022002481A2 (es) 2019-06-11
RS65595B1 (sr) 2024-06-28
FI4050034T3 (fi) 2024-06-10
SA523442262B1 (ar) 2024-05-19
CR20220578A (es) 2023-01-17
IL313895A (en) 2024-08-01
US11505606B2 (en) 2022-11-22
CN117603353A (zh) 2024-02-27
RU2022103374A (ru) 2022-03-02
US11421027B2 (en) 2022-08-23
CN109843325A (zh) 2019-06-04
PE20190976A1 (es) 2019-07-09
KR102505681B1 (ko) 2023-03-06
US20200048348A1 (en) 2020-02-13
WO2018052503A1 (en) 2018-03-22
IL265321A (en) 2019-05-30
RU2019111037A (ru) 2020-10-15
CN114395048A (zh) 2022-04-26
US20230082151A1 (en) 2023-03-16
CL2021003289A1 (es) 2022-07-15
KR102507537B1 (ko) 2023-03-08
HUE066651T2 (hu) 2024-08-28
JP2019536430A (ja) 2019-12-19
KR20190052048A (ko) 2019-05-15
DOP2023000165A (es) 2023-10-15
US20230272075A1 (en) 2023-08-31
JP2022061993A (ja) 2022-04-19
BR112019004873A2 (pt) 2019-06-11
LT4050034T (lt) 2024-06-10
JP7030109B2 (ja) 2022-03-04
JP2024023251A (ja) 2024-02-21
BR122022002481A8 (pt) 2023-02-07
ES2980623T3 (es) 2024-10-02
MX2019002967A (es) 2019-07-04
AU2017327723A1 (en) 2019-05-02
PL4050034T3 (pl) 2024-07-22
HRP20240767T1 (hr) 2024-09-13
EP4417263A2 (en) 2024-08-21
US20220025047A1 (en) 2022-01-27
IL290517B1 (en) 2024-08-01
ECSP19026304A (es) 2019-06-30
CL2021003290A1 (es) 2022-07-15
EP3512549A1 (en) 2019-07-24
IL290517A (en) 2022-04-01
IL265321B1 (en) 2023-09-01
CL2022003769A1 (es) 2023-07-21
MX2022002018A (es) 2022-03-11

Similar Documents

Publication Publication Date Title
PE20241349A1 (es) Anticuerpos de union a cd3
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
CL2022002448A1 (es) Constructos de anticuerpo para flt3 y cd3 (divisional sol.: 201800269)
AR117727A1 (es) Anticuerpos que se unen a cd3
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
CL2018000263A1 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3.
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
MX2019000730A (es) Proteinas multiespecificas de union al antigeno y metodos de uso de estas.
CO2019013654A2 (es) Receptores de antígenos quiméricos que se dirigen a flt3
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
MX2022006461A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
PE20131209A1 (es) Anticuerpos anti-fap
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
AR114284A1 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
AR091961A1 (es) Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b)
CL2008003779A1 (es) Anticuerpo bivalente bioespecifico que consta de las cadenas ligeras y pesadas de anticuerpos que se une a un primer y segundo antigeno, en el que los dominios constantes cl y ch1 y variables vl y vh, de las cadenas del anticuerpo para el segundo antigeno, se reemplazan entre si; metodo de producción; composición farmaceutica.
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
PE20171060A1 (es) Receptores quimericos de antigeno anti-cldn y metodos de uso